Premium
Prostate cancer screening
Author(s) -
Alexander Freda E.
Publication year - 2000
Publication title -
microscopy research and technique
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 118
eISSN - 1097-0029
pISSN - 1059-910X
DOI - 10.1002/1097-0029(20001201)51:5<419::aid-jemt3>3.0.co;2-4
Subject(s) - prostate cancer , medicine , cancer , asymptomatic , randomized controlled trial , intensive care medicine , prostate , oncology , prostate cancer screening , identification (biology) , public health , gynecology , prostate specific antigen , pathology , biology , botany
Prostate cancer is an important and growing public health problem. PSA testing is able to lead to the identification of large numbers of cases of prostate cancer while still asymptomatic. This provides the potential for important reductions in prostate cancer mortality through the introduction of screening programs. The most reliable evidence that this potential can be realised can only come from randomised controlled trials (RCTs). Alternative sources of evidence are compared with that from RCTs; the costs of a wrong decision would be high and it is argued that the case for RCTs is clear. Microsc. Res. Tech. 51:419–422, 2000. © 2000 Wiley‐Liss, Inc.